Canagliflozin effects include weight loss in phase III placebo-controlled trial

Treatment with canagliflozin was associated with significant weight loss as well as improvements in glycemic control, when compared with placebo in a 26-week, phase III study of nearly 600...

Field of Interest: Cardiology